Translational Psychiatry
August 29, 2025
Anton L. V. Avanceña, Linh N. Vuong, James G. Kahn et al.
8 citations
Abstract Psilocybin-assisted therapy (PAT) has been shown in early trials to reduce the symptoms of treatment-resistant depression (TRD). This study evaluated the cost-effectiveness of PAT as a third-line treatment for major depressive disorder compared to standard of care (SOC). We used an individual-level, probabilistic simulation model that portrays representative US adults with TRD who...
Journal of Advances in Medicine and Medical Research
August 28, 2025
O. Ogundeji, Nkechinyere M Harry, Akinyemi Akinwumiju et al.
Major Depressive Disorder (MDD) affects approximately 280 million people globally, with current treatments showing significant limitations, including delayed onset of action, low remission rates, and troublesome side effects. Esmethadone (REL-1017, d-methadone) has emerged as a promising agent for MDD. This review examines esmethadone (REL-1017), a novel glutamatergic modulator functioning...
Mindfulness
August 28, 2025
Fang Fei Lyu, Vimala Ramoo, Ping Lei Chui et al.
Exercise has known benefits for bone, physical, and mental health. This study aimed to determine the effects of a tailored mindful exercise program on back pain, balance, kinesiophobia, mindfulness, anxiety, and depression in older patients with primary osteoporosis. A two-arm randomized controlled trial (RCT) was conducted in a hospital setting in Kunming, China. Eligible patients were...
European Psychiatry
August 26, 2025
Ismaël Conejero, Raquel Alvarez García, Alejandro Porras-Segovia et al.
2 citations
Esketamine has been shown to produce a major antidepressant response in patients with treatment-resistant depression (TRD). We evaluated the factors associated with achieving remission in these individuals. The study was carried out across four psychiatry departments in Madrid, Spain. Patients aged over 18 years were included if they received esketamine as an augmentation treatment for TRD....
The American Journal of Drug and Alcohol Abuse
August 22, 2025
P. Manza, Annabelle M. Belcher, Heather Fitzsimons et al.
ABSTRACT Background: Opioid use disorder (OUD) is a chronic relapsing condition with a high mortality rate. While medications such as methadone are valuable first-line therapies, retention is poor, with the highest dropout rates early in a treatment attempt. Poor outcomes are due in part to the very high rates of co-morbid depression in people with OUD, as depression can drive opioid use....
Behavioural Pharmacology
August 21, 2025
Stephen W. White, Tara D. Clover, Kenneth J. Sufka
Pre- and probiotics promote a diverse and functional gut microbiota and have demonstrated both anxiolytic and antidepressant effects; however, how synbiotic diet interacts with antidepressant medications has not been fully investigated. This study sought to evaluate the potential anxiolytic or antidepressant effects of a synbiotic diet in an avian model that presents homologies with...
arXiv Preprint Archive
August 21, 2025
Karin Vadovičová
preprint
My findings show what causes loss of awareness, anesthesia, memory replay, opioid induced respiratory depression (OIRD), and slow-wave sleep (SWS). Opiates are fast pain relievers and anesthetics that can cause respiratory arrest. I found how mu-opioids and anesthetics by activating medial habenula (MHb) and/or interpeduncular nucleus (IPN) induce unawareness and slowdown respiration. MHb...
The International Journal of Psychiatry in Medicine
August 20, 2025
Harold G. Koenig
of
Frontiers in Psychiatry
August 19, 2025
Hebert W. Harris
This paper introduces Active Intersubjective Inference (AISI), a novel framework that integrates psychodynamic theory with predictive processing to explain self-identity construction and psychopathology. AISI posits that the self emerges from recursive inferences about how others perceive us (second-order self), interacting bidirectionally with interoceptive processes. We map psychodynamic...
The International Journal of Neuropsychopharmacology
August 18, 2025
B Baune, E Van Assche
Abstract Background DNA methylation is a biomarker suited to investigate dynamic processes, such as treatment response. For this analysis we focus on DNA methylation changes during a randomised controlled trial (RCT) in treatment resistant depressed patients comparing racemic ketamine (s.c.) versus midazolam (s.c.) (the Ketamine for Adult Depression Study - KADS). This clinical trial showed a...